(Q36918107)

17 August 2017

1 reference

title

Pharmacogenetics of thiazolidinedione therapy (English)

1 reference

17 August 2017

author name string

Christina L Aquilante

series ordinal

1

1 reference

17 August 2017

publication date

1 August 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

917-931

1 reference

Type 2 diabetes: principles of pathogenesis and therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Pharmacogenomics: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Sequence variation in PPARG may underlie differential response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Isolation of cDNAs for perilipins A and B: sequence and expression of lipid droplet-associated proteins of adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Rosiglitazone--continued uncertainty about safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

Novel insulin sensitizers: pharmacogenomic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

What Genome-wide Association Studies Can Do for Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.8.917

21 January 2018

Identifiers

DOI

10.2217/14622416.8.8.917

1 reference

17 August 2017

1 reference